<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452149</url>
  </required_header>
  <id_info>
    <org_study_id>ALLEVIATE-HF</org_study_id>
    <nct_id>NCT04452149</nct_id>
  </id_info>
  <brief_title>Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure</brief_title>
  <acronym>ALLEVIATE-HF</acronym>
  <official_title>Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ALLEVIATE-HF study is a prospective, randomized, multi-site, interventional,
      investigational device exemption (IDE) study. The purpose of the study is to gain experience
      with utilization of an integrated device diagnostic-based risk stratification algorithm to
      guide patient care in subjects with NYHA class II and III heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will utilize the market released Reveal LINQ™ Insertable Cardiac Monitor with an
      investigational ALLEVIATE-HF RAMware download. The study will enroll up to 300 subjects at up
      to 30 sites in the US, and will characterize the safety of the patient management pathway.
      Subjects will be followed for a minimum of 7 months, and until study closure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following LINQ™ device insertion, subjects will be randomly allocated in a 2:1 ratio to either the observation arm or the intervention arm. Subjects in the observation arm will start with an observational period of 7 months and then transition to the intervention arm for the remainder of their participation in the study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the patient management pathway (i.e. proportion of medication interventions with associated medication intervention related serious adverse events)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of medication interventions with one or more associated medication intervention related SAEs will be evaluated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure NYHA Class II</condition>
  <condition>Heart Failure NYHA Class III</condition>
  <arm_group>
    <arm_group_label>Observation Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed per standard of care without visibility to the heart failure sensor data. Subjects will transition to the intervention arm after 7 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a Reveal LINQ™ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download, and will be managed using an integrated device diagnostic-based risk stratification algorithm combined with a clinical medication plan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download</intervention_name>
    <description>Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_label>Observation Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication intervention</intervention_name>
    <description>Risk status guided medication intervention.</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has NYHA Class II or III heart failure per most recent assessment,
             irrespective of left ventricular ejection fraction (LVEF)

          -  Patient has documented recent history of symptomatic heart failure, defined as meeting
             any one of the following three criteria: 1. Hospital admission with primary diagnosis
             of HF within the last 12 months, OR 2. Intravenous HF therapy (e.g. IV
             diuretics/vasodilators) or ultrafiltration within the last 6 months, OR 3. Patient had
             the following BNP/NT-proBNP6 within the last 3 months: If LVEF ≥ 50%, then BNP&gt; 150
             pg/ml or NT-proBNP &gt; 450 pg/ml OR If LVEF is &lt;50%, then BNP&gt; 300 pg/ml or NT-proBNP &gt;
             900 pg/ml

          -  Patient is willing and able to comply with the protocol, including LINQ ICM insertion,
             CareLink transmissions (including adequate connectivity), study visits and remote care
             directions.

          -  Patient is 18 years of age or older.

          -  Patient has a life expectancy of 12 months or more.

        Exclusion Criteria:

          -  Patient is currently implanted with a cardiovascular implantable electronic device
             (CIED) (e.g. ICM6, pacemaker, ICD, CRT-D or CRT-P device) or hemodynamic monitor.

          -  Patient is receiving temporary or permanent mechanical circulatory support.

          -  Patient had MI or PCI/CABG within past 90 days.

          -  Patient has had a heart transplant, or is currently on heart transplant list.

          -  Patient has severe valve stenosis on echocardiogram.

          -  Patient has primary pulmonary hypertension (pre-capillary, WHO group 1,3,4,5).

          -  Patient is on chronic intravenous inotropic drug therapy (e.g. dobutamine, milrinone).

          -  Patient has severe renal impairment (eGFR &lt;30 mL/min).

          -  Patient has systolic blood pressure of &lt; 90 mmHg at the time of enrollment.

          -  Patient is on chronic renal dialysis.

          -  Patient is unable to undergo one round of PRN medication intervention (i.e. 4 days of
             increased diuretics dose).

          -  Patient has liver disease, defined as AST/ALT &gt;5x normal, or bilirubin &gt;2x normal.

          -  Patient has serum albumin &lt; 3 g/dL.

          -  Patient has hypertrophic obstructive cardiomyopathy, constrictive pericarditis or
             amyloidosis.

          -  Patient has complex adult congenital heart disease.

          -  Patient has active cancer involving chemotherapy and/or radiation therapy.

          -  Patient weighs more than 500 pounds.

          -  Patient is pregnant (all females of child-bearing potential must have a negative
             pregnancy test within 1 week of enrollment).

          -  Patient is enrolled in another interventional study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aimee Laechelt</last_name>
    <phone>(+1-763) 526-2730</phone>
    <email>aimee.a.laechelt@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Joseph's Medical Center</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cyrus Buhari, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bay Area Cardiology Associates PA</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen Mester, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Heart Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34950</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Prasad Chalasani, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Russell Stapleton, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Goerbig-Campbell, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mosi Bennett, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Memorial Health Heart &amp; Vascular Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bobbi Hoppe, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Craig Long, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of North Mississippi</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Barry Bertolet, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Missouri Cardiovascular Specialists</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Stampehl, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Darius Sholevar, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nir Uriel, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cone Health</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>James Allred, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doylestown Health Cardiology a division of Doylestown Health Physicians</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Renee Sangrigoli, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Goldstein, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Field, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frank McGrew, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Methodist Physicians</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Jeffries, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tyler Cardiovascular Consultants</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Raul Torres, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>George Sokos, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Insertable Cardiac Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

